-
CD142/TF/Coagulation Factor III (BSB-143)
CD142/TF/Coagulation Factor III (BSB-143)
- 中文名称：
- CD142/TF/Coagulation Factor III (BSB-143)
- 英文名称：
- CD142/TF/Coagulation Factor III (BSB-143)
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA59362
- 规格：
- 5 Slides|3 mL (RTU)|0.1 mL (Concentrate)|7 mL (RTU)|0.5 mL (Concentrate)
- 保存建议：
- Store at 2-8 degree C (Control Slides: Store at 20-25 degree C)
- 货期：
- 6-8周
- 来源宿主：
- Mouse
- 反应种属：
- Human, Mouse, Rat
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 其他：
克隆性:Monoclonal
同型:IgG2b
克隆号:[BSB-143]
特异性:N/A
纯度:N/A
形式：Paraffin, Frozen
CD142 is a rabbit monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH7.5, containing BSA and sodium azide as a preservative.
浓度：N/A
- 说明书：
CD142, also known as Tissue Factor (TF) or Coagulation Factor III or Thromboplastin, is encoded by the F3 gene located on chromosome 1p21.3. CD142 /TF is a 46 kDa sized integral membrane glycoprotein. Upon complex formation with coagulation factor VII, extrinsic blood coagulation is activated by a catalytic cascade that involves specific proteolysis.
CD142 antibody is not only associated with the progression, but also with the overall survival rate of many cancers, including breast, gastrointestinal, liver, pancreatic, and prostate cancer. A study that investigated CD142 antibody expression in non-small-cell lung cancer (NSCLC) found that immunohistochemical staining was increased in NSCLC patients with metastasis, compared to patients without metastasis, indicating the critical role of CD142 in the progression of NSCLC. A study found increased CD142 levels in breast cancer tissue as well as a correlation between poor survival and high levels of CD142 expression in breast cancer patients. Overexpression of TF in fibrosarcoma, in gastric cancer cells and in melanoma cells enhances tumour growth by diminishing the transcription of antiangiogenic thrombospondins and/or by increasing the transcription of pro-angiogenic VEGF.
The SARS-CoV-2 virus triggers the synthesis and release of pro-inflammatory cytokines, including IL-6 and TNF-alpha and also promotes downregulation of ACE-2, which promotes a concomitant increase in levels of angiotensin II (AT-II). Both TNF-alpha and AT-II have been implicated in promoting overexpression of tissue factor (TF) in platelets and macrophages. Additionally, the generation of antiphospholipid antibodies associated with COVID-19 may also promote an increase in TF. TF may be a critical mediator associated with the development of thrombotic phenomena in COVID-19.
